Immuneering Corporation (NASDAQ:IMRX) Receives $16.50 Consensus Price Target from Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of research firms recently weighed in on IMRX. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Immuneering in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Finally, Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th.

Immuneering Stock Performance

IMRX stock opened at $4.19 on Friday. Immuneering has a one year low of $1.66 and a one year high of $10.08. The company’s fifty day moving average price is $5.17 and its 200-day moving average price is $5.43. The company has a market capitalization of $271.09 million, a PE ratio of -3.58 and a beta of 0.38.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.09. On average, research analysts predict that Immuneering will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IMRX. Jane Street Group LLC purchased a new position in shares of Immuneering in the first quarter valued at $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Immuneering in the fourth quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering in the third quarter valued at $35,000. Levin Capital Strategies L.P. bought a new stake in Immuneering in the first quarter worth $53,000. Finally, Cetera Investment Advisers bought a new stake in Immuneering in the first quarter worth $67,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.